email article
A topical atopic dermatitis (AD) treatment derived from skin bacteria demonstrated safety and preliminary evidence of clinical activity in a proof-of-principle study.
After seven days of treatment, MSB-0221 significantly reduced
Staphylococcus aureus colonization in
S. aureus toxin PSM-alpha. The compound inhibited inflammation-inducing toxin irrespective of its activity against
S. aureus. A post hoc evaluation limited to patients with confirmed
S. aureus killing suggested improvement in local eczema severity.
Patients treated with MSB-0221 had fewer AD-related adverse events (AEs) as compared with patients treated with a topical delivery substance (vehicle) without
S. hominis (
ShA9), a naturally occurring skin bacteria incorporated into MSB-0221, reported Richard L. Gallo, MD, PhD, of the University of California San Diego, and colleagues in